NCT04313400: A trial that was reported late by Amytrx Therapeutics, Inc.
This trial has reported, although it was 74 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT04313400 |
|---|---|
| Title | A Two Part, Phase I/II, Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study of the Safety and Efficacy of Topically Applied AMTX-100 CF in Adult Patients With Mild to Moderate Atopic Dermatitis |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 10, 2020 |
| Completion date | Dec. 19, 2023 |
| Required reporting date | Dec. 18, 2024, midnight |
| Actual reporting date | March 3, 2025 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 74 |